Comparison of Topical Latanoprost vs Topical Corticosteroid in Treatment of Localized Alopecia Areata

Learn more about:
Related Clinical Trial
A Study With Jaktinib Hydrochloride Cream Applied Topically to Subjects With Alopecia Areata Modified SALT Score for Alopecia Areata Safety and Efficacy of Bimatoprost Solution in Treating Eyelash Loss or Hypotrichosis in Children Comparative Study Examining the Effectiveness in Use of a DERMOJET and a Normal Syringe Treatment for Patients With Hair Loss – Alopecia Areata TREg Activation in the Treatment of the PELADE (Alopecia Areata) The Effectiveness of Mindfulness Based Cognitive Group Therapy for Social Anxiety Symptoms in People Living With Alopecia Areata Response of Topical Capsaicin in Alopecia Areata Efficacy of Twice Daily Application of LEO 124249 Ointment 30 mg/g for 12 Weeks on Eyebrow Alopecia Areata. Jaktinib Dihydrochloride Monohydrate in Severe Alopecia Areata Study to Evaluate the Safety and Efficacy of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata Follicular Revival in Treatment-resistant Alopecia Areata: Evaluating Use of Micro-needling Cryotherapy Versus Steroids In Alopecia Areata:Trichoscopic Evaluation Efficacy and Tolerability Study of Two Dose Regimens of CTP-543 in Adults With Alopecia Areata Efficacy and Tolerability Study of Two Dosing Regimens of CTP-543 in Adults With Alopecia Areata The Efficiency Of The Methotrexate At Patients Affected By Grave Pelade Stem Cell Educator Therapy in Alopecia Areata Comparative Study for Treatment of Alopecia Areata Using Carboxytherapy and Intralesional Steroids The Comparison Study of Intralesional Botulinum Toxin A and Corticosteroid Injection for Alopecia Areata Adrenal Function and Use of Intralesional Triamcinolone Acetonide 10 mg/mL (Kenalog-10) in Patients With Alopecia Areata Vytorin in the Treatment of Alopecia Areata Combined Restylane and Triamcinolone Acetonide Injections for the Treatment of Alopecia Areata The Efficacy and Safety of Different Concentrations of Localized Injections of Steroids in the Treatment of Alopecia Areata Transepidermal Delivery of Triamcinolone Acetonide or Platelet Rich Plasma Using Either Fractional Carbon Dioxide Laser or Microneedling in Treatment of Alopecia Areata A Trial of Clobetasol Propionate Versus Hydrocortisone in Children With Alopecia Areata Efficacy and Safety of LH-8 in Paediatric Alopecia Areata Comparison of Topical Latanoprost vs Topical Corticosteroid in Treatment of Localized Alopecia Areata Intralesional Steroids in the Treatment of Alopecia Areata A Phase II Study in Patients With Alopecia Areata Topical Crisaborole in Patients With Alopecia Areata Efficacy of Hair Transplantation Compared With Hypodermic Needle Irritation in Alopecia Areata A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata Efficacy of Fractional CO2 Laser as a Mono- or Adjuvant Therapy for Alopecia Areata Characteristics of T Cells From Alopecia Areata Scalp Skin Before and After Treatment With Aldara 5% Efficacy Study of a Cosmetic Lotion in the Treatment of Alopecia Areata in Males and Females Excimer Light for Alopecia Areata Biocellular-Cellular Regenerative Treatment Scaring Alopecia and Alopecia Areata Safety and Efficacy Study of SHAPE Gel in Alopecia Areata Efficacy Study of Latanoprost and Bimatoprost Solutions in Promoting Eyelash Growth in Patients With Alopecia Areata Topical Garlic Concentrate for Alopecia Areata in Children Pilot Study to Evaluate the Efficacy of Ruxolitinib in Alopecia Areata Aldara for the Treatment of Extensive Alopecia Areata A Clinical Trial to Evaluate the Efficacy of Abatacept in Moderate to Severe Alopecia Areata Topical Calcipotriol Versus Narrowband Ultraviolet B in Treatment of Alopecia Areata LEO 124249 Ointment in the Treatment of Alopecia Areata Childhood Alopecia Areata Study Using the 308-nm Excimer Laser Alefacept in Patients With Severe Scalp Alopecia Areata Treatment of Alopecia Areata of the Scalp With Intradermal Injections of Botulinum Toxin Evaluation of the Efficacy and Tolerability of Treatment With Interleukin-2 in Severe and Resistant Alopecia Areata

Brief Title

Comparison of Topical Latanoprost vs Topical Corticosteroid in Treatment of Localized Alopecia Areata

Official Title

A Randomized Comparative Study of Efficacy and Safety of Topical Latanoprost Versus Topical Corticosteroid in the Treatment of Localized Alopecia Areata

Brief Summary

      Alopecia areata (AA) is an autoimmune disease that involves the hair follicles. Topical
      corticosteroids are the established agents for treating this disorder. There are several case
      reports and case series which have demonstrated the efficacy of topical prostaglandins. The
      two agents have not been compared head-to-head in the published literature. The investigators
      attempt to compare the efficacy and safety of topical betamethasone and topical latanoprost
      in the treatment of localised alopecia areata.
    

Detailed Description

      Alopecia areata (AA) is an autoimmune disease that involves the hair follicles. Topical
      corticosteroids are the established agents for treating this disorder. Topical prostaglandins
      like latanoprost have also been used for this disorder. There are several case reports and
      case series which have demonstrated the efficacy of topical prostaglandins. However, the two
      agents i.e. topical corticosteroids and topical latanoprost have not been compared
      head-to-head in the published literature. The investigators attempt to compare the efficacy
      and safety of topical betamethasone and topical latanoprost in the treatment of localised
      alopecia areata.
    

Study Phase

Phase 4

Study Type

Interventional


Primary Outcome

Number of patients with hair regrowth (complete, partial, or no regrowth)

Secondary Outcome

 Number of patients suffering from adverse effects

Condition

Alopecia Areata

Intervention

Topical latanoprost 0.005%

Study Arms / Comparison Groups

 Topical latanoprost
Description:  Topical latanoprost 0.005%

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

50

Start Date

September 2014

Completion Date

March 2015

Primary Completion Date

March 2015

Eligibility Criteria

        Inclusion Criteria:

          -  • Cases of AA involving scalp and beard area, having 5 or less patches in all,
             involving less than 40% area

               -  Stable disease without appearance of new patch or increase in size of existing
                  patch for at least 15 days

        Exclusion Criteria:

          -  • Pregnant and lactating women

               -  Patients on topical treatment for alopecia in the past fifteen days or on
                  systemic treatment for alopecia in the past one month

               -  Presence of any contraindication for topical corticosteroids (local skin
                  infections, skin atrophy) or latanoprost (pregnancy, lactation and dermatitis)

               -  Any other coexisting hair disorder (viz., trichotillomania, androgenetic
                  alopecia, telogen effluvium)

               -  Extensive disease i.e. >5 patches of AA or area involving >40% area / alopecia
                  totalis/ alopecia universalis/ ophiasis
      

Gender

All

Ages

N/A - 99 Years

Accepts Healthy Volunteers

No

Contacts

, , 

Location Countries

India

Location Countries

India

Administrative Informations


NCT ID

NCT02350023

Organization ID

9121/PG-2Trg/12/8073


Responsible Party

Principal Investigator

Study Sponsor

Postgraduate Institute of Medical Education and Research


Study Sponsor

, , 


Verification Date

November 2015